Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

OstiSense Biosensor in Bruxism Reduction - A Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03749928
Recruitment Status : Not yet recruiting
First Posted : November 21, 2018
Last Update Posted : April 10, 2020
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco

Tracking Information
First Submitted Date  ICMJE November 12, 2018
First Posted Date  ICMJE November 21, 2018
Last Update Posted Date April 10, 2020
Estimated Study Start Date  ICMJE July 2020
Estimated Primary Completion Date November 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 19, 2018)
  • Change in frequency of bruxism episodes [ Time Frame: 8 weeks ]
    Evaluating how efficient the OstiSense biosensor tool is in changing the number of bruxism episodes
  • Change in duration of bruxism episodes [ Time Frame: 8 weeks ]
    Evaluating how efficient the OstiSense biosensor tool is in changing the duration of bruxism episodes
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 19, 2018)
  • Self-reported change in frequency of bruxism episodes [ Time Frame: 8 weeks ]
    Self-reported (or reported by sleeping partners in SB) change in frequency of bruxism episodes
  • Self-reported change in pain - change in pain level marked on a visual pain scale [ Time Frame: 8 weeks ]
    Self-reported change in pain (facial pain, myofascial headache) assessed using a visual pain scale with 6 different pain levels indicated by 6 different smileys (from happy smiling to crying) and a pain severity scale from 0 to 10, which includes the smiley faces, with 0 as no pain, 1-2 slight pain, 3-4 mild, 5-6 moderate, 7-8 severe and 9-10 horrible pain
  • Self-reported change in pain - change in yes/no answers on a pain questionnaire [ Time Frame: 8 weeks ]
    Self-reported change in pain (facial pain, myofascial headache) using a pain questionnaires requiring yes and no answers to questions
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE OstiSense Biosensor in Bruxism Reduction - A Clinical Study
Official Title  ICMJE OstiSense Biosensor in Bruxism Reduction - A Clinical Study
Brief Summary The overall objective of the clinical studies with the OstiSense biosensor tool will be to evaluate whether the use of the OstiSense biosensor tool significantly reduces the number of sleep bruxism events per night as well as the duration of those events for patients with bruxism.The product under investigation is the OstiSense biosensor with biofeedback for bruxism therapy. The sensor is integrated in a night-guard like device and registers the pressure created during a bruxism episode. If a predetermined pressure threshold is exceeded, the integrated vibration tool will be activated, and the vibrations will/should remind the wearer to stop clenching his jaws and relax his facial muscles. Due to this feedback, the number of bruxism episodes as well as clenching time per episode should be reduced. The sensor also identifies the time of grinding and the sleep stage of the patient.
Detailed Description

Pilot Study:

30 subjects will be recruited for this pilot study. An oral exam will be performed to check for gingiva and tooth conditions as well as fulfilling inclusion and exclusion criteria as described below. Subjects will be randomly assigned to an active treatment or a control group. OstiSense biosensor feed back tool (night guards) will be delivered to the participant. First patient impressions about wearing comfort will be evaluated, chair side. Then the investigators will test the efficiency of the OstiSense biosensor feedback tool in reduction of numbers of bruxism episodes and reduction of the duration of bruxism episodes (primary outcome). These data will be collected also in order to achieve information for a sample size calculation for a larger subsequent clinical trial. The investigators will collect information about self-reported (or reported by sleeping partners in SB) reduced frequency of bruxism episodes. In addition, self-reported reduction in pain (facial pain, myofascial headache) (secondary outcome) is of interest. Visual pain scales and pain questionnaires will be used as validated instruments for subjective pain assessment.

Active Treatment Group:

Participants will be instructed to wear the biofeedback tool during the night/sleep. They will wear the biofeedback tool for 1 week with biofeedback turned off to record baseline activity. At the 1-week recall, the investigators will check for any comfort issues and will confirm accurate data recording. For 3 more weeks the biofeedback will stay turned off to collect further baseline data.

At the next recall (4-week recall) participants will be interviewed about any wear issues and will be asked to fill out the same questionnaire as used in phase 1 of the pilot study. The biofeedback mechanism will then be turned on (battery insertion). During this meeting subjects will be instructed to test the vibration mechanism by increasing their bite force until vibration occurs, and then to relax their muscles so that vibration stops. Subjects will be asked to repeat this procedure several times to get familiar with the active device and also to learn to relax their muscles when the feedback occurs during night bruxism..

Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week (5-week recall) of the 8 weeks to identify any wear issues while the tool is turned on, and for checking the data recording function. At the end of 8 weeks, participants will be invited for a final recall visit 12-week recall). The same questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.

Control Group:

Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall the investigators will check for any comfort issues and will confirm accurate data recording. After three weeks the investigators will again check on the participant, will identify any wear issues, ask for feedback and will check the data recording function (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). The questionnaire will be provided, and feedback questions will be asked. Data from the smart device about bruxism episodes will be collected.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Bruxism, Sleep
Intervention  ICMJE
  • Device: OstiSense biosensor - active
    The activated biofeedback back night guard will be used to reduce sleep bruxism
  • Device: OstiSensor biosensor - not activated
    A not-activated night guard will be used as control device
Study Arms  ICMJE
  • Experimental: OstiSense biosensor - active
    Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
    Intervention: Device: OstiSense biosensor - active
  • Placebo Comparator: OstiSensor biosensor - not activated
    Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
    Intervention: Device: OstiSensor biosensor - not activated
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: November 19, 2018)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2020
Estimated Primary Completion Date November 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • age 18 to 65 years, in good general health
  • the occlusion is stable with at least 8 lower teeth (including several lower front teeth)
  • willing to comply with all study procedures and protocols
  • must be able to read and understand English
  • have an understanding of the study
  • able to provide written informed consent in English
  • willing to sign the "Authorization for Release of Personal Health Information and Use of Personally Unidentified Study Data for Research" form; data will only be used for research.

Exclusion Criteria:

  • having acute temporo mandibular joint pain or a history of acute temporo mandibular joint pain
  • having used a biofeedback tool for bruxism reduction before
  • subjects not having a smart phone device
  • subjects not willing to use their smart phone device for data collection related to their bruxism
  • heavily crowed lower teeth (difficult to integrate a night guard)
  • wearing complete dentures
  • show evidence of extremely poor oral hygiene
  • subjects at extreme high caries risk
  • subjects with pacemakers
  • subjects suffering from systemic diseases, significant past or medical history with conditions that may affect oral health or oral flora (i.e. diabetes, HIV, heart conditions that require antibiotic prophylaxis),
  • taking medications that may affect the oral flora or salivary flow (e.g. antibiotic use in the past three months, drugs associated with dry mouth / xerostomia [extreme high caries risk])
  • other conditions that may decrease the likelihood of adhering to study protocol
  • subjects who will leave the area and are unable to complete the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Peter Rechmann, DMD, PhD 415 514 3225 Peter.Rechmann@ucsf.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03749928
Other Study ID Numbers  ICMJE P0533276
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party University of California, San Francisco
Study Sponsor  ICMJE University of California, San Francisco
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Peter Rechmann, DMD, PhD UCSF School of Dentistry
PRS Account University of California, San Francisco
Verification Date April 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP